Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity

• Published in: Ageing research reviews Vol. 103; p. 102595
• Main Authors: Zhang, Yujie, Chen, Jie, Li, Yanru, Jiao, Bin, Luo, Shilin
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.01.2025
• Subjects: Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides - antagonists & inhibitors; Amyloid beta-Peptides - immunology; Amyloid beta-Peptides - metabolism; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antibody; Clinical trial; Clinical Trials as Topic; Disease-modifying therapies; Humans; Clinical trial; Disease-modifying therapies; Antibody; Alzheimer's disease

The U.S. Food and Drug Administration (FDA) recently approved lecanemab and donanemab for the treatment of early symptomatic Alzheimer's disease (AD) after their phase III trials reached endpoints. These two anti-amyloid β monoclonal antibodies represent the latest promise of disease-modifying...